How can we recognize "disease modification" effects?
Siemers
E R
ER
Alzheimer's Disease Team, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. esiemers@lilly.com
D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D015415:Biomarkers / Q000032:analysis*; D002986:Clinical Trials as Topic; D006801:Humans; D016896:Treatment Outcome
D015415:Biomarkers